Coronary Heart Disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Aged =18 years, male or female. (2) Meeting the diagnostic criteria for residual inflammatory risk in chronic coronary syndrome (Western medicine diagnosis), and meeting the diagnostic criteria for Qi Deficiency and Blood Stasis with Phlegm-Turbidity Syndrome (Traditional Chinese Medicine diagnosis). (3) No use of antibiotics, steroids or other hormonal medications, or Chinese herbal preparations within the past month. (4) Voluntarily participating in this trial and providing signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with severe conditions including: severe heart failure (NYHA Class IV or left ventricular ejection fraction =30%), malignant arrhythmia, aortic dissection, circulatory failure, shock, tension pneumothorax, acute pulmonary embolism, respiratory failure, or other thoracic skin/tissue/chest wall pathologies. (2) Patients with concurrent infections originating from other systems, such as pneumonia, urinary tract infection, or gastrointestinal inflammation. (3) Patients with severe hepatic or renal impairment (ALT > 3 times the upper limit of normal and/or Scr = 265 µmol/L). (4) Patients with severe hematological diseases, neurological or psychiatric disorders, or malignant tumors. (5) Women who are pregnant, lactating, or planning for pregnancy. (6) Patients currently participating in other clinical trials. (7) Patients with a known allergy to the investigational drug(s).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High-sensitivity C-reactive protein;Neutrophil extracellular traps;Interleukin-6;Absolute neutrophil count and percentage; | — |
Secondary
| Measure | Time frame |
|---|---|
| ajor Adverse Cardiovascular Events;TCM Syndrome Score;Seattle Angina Questionnaire (SAQ) Score; | — |
Countries
China
Contacts
Fangcun Hospital, Guangdong Provincial Hospital of Chinese Medicine